Personal protective equipment (PPE) related adverse skin reactions among healthcare workers at the main COVID-19 isolation center in Barbados.
Barbados
COVID-19
PPE
adverse skin reactions
healthcare workers
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
06
2022
accepted:
12
09
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
1
11
2022
Statut:
epublish
Résumé
The use of personal protective equipment (PPE) reduces the risk of transmission of infectious agents significantly among healthcare workers (HCWs). The study aimed to investigate the prevalence and characteristics of PPE-related adverse skin reactions among HCWs working at the main COVID-19 isolation center in Barbados. A cross-sectional web-based online survey was conducted during April to June 2021 which recorded demographic information, details of PPE use and adverse skin reactions including severity and duration of onset of symptoms. Most of the respondents used PPE for consecutive days (77.9%), 1-6 h/day (59.2%), and more than a year (62.5%). Fewer than half of the participants (45.6%) experienced adverse skin reactions from the use of PPE. The reactions were mostly observed in the cheeks (40.4%) and nose bridges (35.6%). Females had more reactions than their male counterparts ( The PPE-related skin reactions were common among HCWs which mainly occurred due to prolonged use. Preventive measures inclusive of appropriate training of HCWs on the use of PPE are recommended to minimize these adverse events.
Sections du résumé
Background
The use of personal protective equipment (PPE) reduces the risk of transmission of infectious agents significantly among healthcare workers (HCWs). The study aimed to investigate the prevalence and characteristics of PPE-related adverse skin reactions among HCWs working at the main COVID-19 isolation center in Barbados.
Methods
A cross-sectional web-based online survey was conducted during April to June 2021 which recorded demographic information, details of PPE use and adverse skin reactions including severity and duration of onset of symptoms.
Results
Most of the respondents used PPE for consecutive days (77.9%), 1-6 h/day (59.2%), and more than a year (62.5%). Fewer than half of the participants (45.6%) experienced adverse skin reactions from the use of PPE. The reactions were mostly observed in the cheeks (40.4%) and nose bridges (35.6%). Females had more reactions than their male counterparts (
Conclusion
The PPE-related skin reactions were common among HCWs which mainly occurred due to prolonged use. Preventive measures inclusive of appropriate training of HCWs on the use of PPE are recommended to minimize these adverse events.
Identifiants
pubmed: 36304246
doi: 10.3389/fpubh.2022.978590
pmc: PMC9592812
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
978590Informations de copyright
Copyright © 2022 Bharatha, Krishnamurthy, Cohall, Rahman, Forde, Corbin-Harte, Ojeh, Kabir, Parsa, Rabbi and Majumder.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Dermatol Ther. 2020 Jul;33(4):e13310
pubmed: 32170800
Int J Epidemiol. 2020 Jun 1;49(3):717-726
pubmed: 32086938
J Wound Care. 2020 May 2;29(5):245-259
pubmed: 32421479
Prev Med. 2020 Dec;141:106263
pubmed: 33017601
Contact Dermatitis. 2006 Nov;55(5):291-4
pubmed: 17026695
JAAD Int. 2021 Dec;5:85-95
pubmed: 34485949
J Occup Environ Med. 2021 Feb 1;63(2):e80-e85
pubmed: 33298757
J Infect. 2004 Oct;49(3):210-5
pubmed: 15337337
BMJ Open. 2021 Jan 20;11(1):e046199
pubmed: 33472794
J Infect. 2020 Jul;81(1):107-114
pubmed: 32335167
Arch Environ Occup Health. 2022;77(1):1-8
pubmed: 33063614
Clin Dermatol. 2020 Nov - Dec;38(6):785-787
pubmed: 33341217
Dermatitis. 2021 Mar-Apr 01;32(2):78-85
pubmed: 33273243
Acta Neurol Scand. 2006 Mar;113(3):199-202
pubmed: 16441251
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Anaesthesia. 2020 Jul;75(7):920-927
pubmed: 32246849
J Am Acad Dermatol. 2020 May;82(5):1215-1216
pubmed: 32171808
Am J Emerg Med. 2020 Sep;38(9):1727-1731
pubmed: 32738467
Lancet Glob Health. 2020 Jun;8(6):e790-e798
pubmed: 32573443
Surg Neurol Int. 2020 Dec 16;11:441
pubmed: 33408926
Cureus. 2021 Sep 15;13(9):e17990
pubmed: 34667668
Am J Infect Control. 2021 Oct;49(10):1305-1315
pubmed: 33965463
Adv Wound Care (New Rochelle). 2020 Jul;9(7):357-364
pubmed: 32320359
Acta Dermatovenerol Alp Pannonica Adriat. 2020 Sep;29(3):115-122
pubmed: 32975297
Indian J Crit Care Med. 2021 Feb;25(2):134-139
pubmed: 33707889
Anaesthesia. 2021 Jan;76(1):91-100
pubmed: 32932556
J Hosp Infect. 2021 Jul;113:180-186
pubmed: 33940089
Health Secur. 2019 Jul/Aug;17(4):324-333
pubmed: 31433277
Dermatol Ther. 2020 Nov;33(6):e14346
pubmed: 32985745
Br J Dermatol. 2020 Jul;183(1):190-192
pubmed: 32255197
Health Secur. 2021 Mar-Apr;19(2):140-149
pubmed: 33175583
EClinicalMedicine. 2020 Jun 27;24:100424
pubmed: 32766539
Nurs Stand. 2009 Jul 15-21;23(45):64, 66, 68 passim
pubmed: 19678520
Curr Opin Infect Dis. 2016 Aug;29(4):400-6
pubmed: 27257793
J Multidiscip Healthc. 2021 Nov 30;14:3309-3319
pubmed: 34876817
Medicine (Baltimore). 2020 Jun 12;99(24):e20603
pubmed: 32541493
Expert Rev Vaccines. 2021 Sep;20(9):1167-1175
pubmed: 34224292
Int Wound J. 2021 Jun;18(3):312-322
pubmed: 33507634
FASEB Bioadv. 2022 Mar 24;4(6):379-390
pubmed: 35601057
PLoS One. 2021 Apr 29;16(4):e0250869
pubmed: 33914813
J Am Acad Dermatol. 2021 Feb;84(2):486-494
pubmed: 33011325
Intensive Crit Care Nurs. 2017 Feb;38:1-9
pubmed: 27836262
Int J Dermatol Venereol. 2020 Mar 13;:
pubmed: 34192087
Pan Afr Med J. 2020 Oct 13;37:148
pubmed: 33425181
Clin Exp Dermatol. 2021 Jan;46(1):142-144
pubmed: 32705718